pulmonary arterial hypertension pah market 2027
DelveInsight's 'Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2016-2027
Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm
The DelveInsight Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the Pulmonary Arterial Hypertension by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension in the US, Europe, and Japan.
Pulmonary Arterial Hypertension Epidemiology
The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Prevalent cases, Sub-type specific prevalent cases and Gender-specific prevalent cases) scenario of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total prevalent population of Pulmonary Arterial Hypertension (PAH) was found to be 70,557 in the year 2016.
Pulmonary Arterial Hypertension Drug Chapters
This segment of the Pulmonary Arterial Hypertension report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, the companies are developing therapeutic molecules based on Gene Therapy and Endothelin receptor antagonists which are contributing towards the market size of IPF. Detailed chapter for upcoming therapies like Aurora-GT (United Therapeutics Corporation), Macitentan (Actelion Pharmaceuticals) and Ralinepag (Arena Pharmaceuticals) have been covered in the report.
Pulmonary Arterial Hypertension Market Outlook
The Pulmonary Arterial Hypertension market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Pulmonary Arterial Hypertension in 7MM was found to be USD 4360.2 million in 2016.
Pulmonary Arterial Hypertension Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Pulmonary Arterial Hypertension Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Pulmonary Arterial Hypertension Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Pulmonary Arterial Hypertension Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Pulmonary Arterial Hypertension market
• Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension market
• To understand the future market competition in the Pulmonary Arterial Hypertension market.
1. Key Insights
2. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance
2.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2016
2.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2027
3. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Classification of Pulmonary Arterial Hypertension (PAH)
3.4. Functional Classification of PAH
3.5. Etiology
3.6. Risk factors
3.7. Pathophysiology
3.8. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]
5. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)
5.1. The United States
5.1.1. Total Prevalent Patient Population of PAH in the United States
5.1.2. Sub-type Specific Prevalence of PAH in the United States
5.1.3. Gender specific Prevalence of PAH in the United States
5.2. Germany
5.2.1. Total Prevalent Patient Population of PAH in Germany
5.2.2. Sub-type Specific Prevalence of PAH in Germany
5.2.3. Gender specific Prevalence of PAH in Germany
5.3. France
5.3.1. Total Prevalent Patient Population of PAH in France
5.3.2. Sub-type Specific Prevalence of PAH in France
5.3.3. Gender specific Prevalence of PAH in France
5.4. Italy
5.4.1. Total Prevalent Patient Population of PAH in Italy
5.4.2. Sub-type Specific Prevalence of PAH in Italy
5.4.3. Gender specific Prevalence of PAH in Italy
5.5. Spain
5.5.1. Total Prevalent Patient Population of PAH in Spain
5.5.2. Sub-type Specific Prevalence of PAH in Spain
5.5.3. Gender specific Prevalence of PAH in Spain
5.6. The United Kingdom
5.6.1. Total Prevalent Patient Population of PAH in the UK
5.6.2. Sub-type Specific Prevalence of PAH in the UK
5.6.3. Gender specific Prevalence of PAH in the United Kingdom
5.7. Japan
5.7.1. Total Prevalent Patient Population of PAH in Japan
5.7.2. Sub-type Specific Prevalence of PAH in Japan
5.7.3. Gender specific Prevalence of PAH in Japan
6. Treatment Algorithm
6.1. Current Treatment Practices
6.2. Treatment Guidelines
6.2.1. CHEST Guidelines [The United States]
6.3. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines
7. Unmet Needs
8. Marketed Drugs
8.1. Approval and Market Presence
9. Marketed Drugs by Companies
9.1. United Therapeutics Corporation
9.2. Actelion Pharmaceuticals Ltd.
9.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
9.4. Bayer AG
9.5. Pfizer
10. Safety and Efficacy of Marketed Drugs
11. Emerging Therapies
11.1. Emerging Drugs Analysis
12. Global Market Size of Pulmonary Arterial Hypertension (PAH)
12.1. Assumptions
12.2. Market Outlook
12.3. Market Size
13. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis
13.1. Key Findings
13.2. Total Market Size of PAH in 7MM
14. Pulmonary Arterial Hypertension (PAH): Market Outlook by Region
15. United States
15.1. Market Outlook
15.2. Assumptions
15.3. Total Market size of PAH
15.4. PAH Market Size by Therapeutic Class
15.5. PAH Market Size by Therapies
16. EU5 Countries
16.1. Market Outlook
16.2. Assumptions
16.3. Germany
16.3.1. Total Market size of PAH
16.3.2. PAH Market Size by Therapeutic Class
16.3.3. PAH Market Size by Therapies
16.4. France
16.4.1. Total Market size of PAH
16.4.2. PAH Market Size by Therapeutic Class
16.4.3. PAH Market Size by Therapies
16.5. Italy
16.5.1. Total Market size of PAH
16.5.2. PAH Market Size by Therapeutic Class
16.5.3. PAH Market Size by Therapies
16.6. Spain
16.6.1. Total Market size of PAH
16.6.2. PAH Market Size by Therapeutic Class
16.6.3. PAH Market Size by Therapies
16.7. United Kingdom
16.7.1. Total Market size of PAH
16.7.2. PAH Market Size by Therapeutic Class
16.7.3. PAH Market Size by Therapies
16.8. Japan
16.8.1. Market Outlook
16.8.2. Assumptions
16.8.3. Total Market size of PAH
16.8.4. PAH Market Size by Therapeutic Class
16.8.5. PAH Market Size by Therapies
17. Rest of World (ROW)
17.1. Assumptions
17.2. Total Market size of PAH
18. Rest of Europe (ROE)
18.1. Assumptions
18.2. Total Market size of PAH
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
List of Tables:
Table 1 Total Prevalent Patient Population of PAH in 7MM (2016-2027)
Table 2 Total Prevalent Population of PAH in the United States (2016-2027)
Table 3 Sub-type Specific Prevalence of PAH in the United States (2016-2027)
Table 4 Gender specific Prevalence of PAH in the United States (2016-2027)
Table 5 Total Prevalent Population of PAH in Germany (2016-2027)
Table 6 Sub-type Specific Prevalence of PAH in Germany (2016-2027)
Table 7 Gender specific Prevalence of PAH in Germany (2016-2027)
Table 8 Total Prevalent Population of PAH in France (2016-2027)
Table 9 Sub-type Specific Prevalence of PAH in France (2016-2027)
Table 10 Gender specific Prevalence of PAH in France (2016-2027)
Table 11 Total Prevalent Population of PAH in Italy (2016-2027)
Table 12 Sub-type Specific Prevalence of PAH in Italy (2016-2027)
Table 13 Gender specific Prevalence of PAH in Italy (2016-2027)
Table 14 Total Prevalent Population of PAH in Spain (2016-2027)
Table 15 Sub-type Specific Prevalence of PAH in Spain (2016-2027)
Table 16 Gender specific Prevalence of PAH in Spain (2016-2027)
Table 17 Total Prevalent Population of PAH in the UK (2016-2027)
Table 18 Sub-type Specific Prevalence of PAH in the UK (2016-2027)
Table 19 Gender specific Prevalence of PAH in the UK (2016-2027)
Table 20 Total Prevalent Population of PAH in Japan (2016-2027)
Table 21 Sub-type Specific Prevalence of PAH in Japan (2016-2027)
Table 22 Gender specific Prevalence of PAH in Japan (2016-2027)
Table 23 Marketed Drugs for Pulmonary Arterial Hypertension - Approval and Market presence
Table 24 Marketed Drugs developed by United Therapeutics Corporation
Table 25 Marketed Drugs developed by Actelion Pharmaceuticals Ltd.
Table 26 Marketed Drugs developed by GlaxoSmithKline Pharmaceuticals/ Gilead Sciences Inc.
Table 27 Marketed Drugs developed by Bayer (AG)
Table 28 Marketed Drugs developed by Pfizer
Table 29 Safety and Efficacy of Marketed Drugs
Table 30 Global Market Size of PAH in USD Million (2016-2027)
Table 31 Global Market Size of Pulmonary Arterial Hypertension (PAH) in USD Million (2015-2025)
Table 32 7 Major Market Size of PAH in USD Million (2016-2027)
Table 33 The US Market size of PAH in USD Million (2016-2027)
Table 34 The U.S. Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Table 35 The US market size of PAH by Therapies in USD Million (2016-2027)
Table 36 Germany Market size of PAH in USD Million (2016-2027)
Table 37 Germany Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Table 38 Germany market size of PAH by Therapies in USD Million (2016-2027)
Table 39 France Market size of PAH in USD Million (2016-2027)
Table 40 France Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Table 41 France market size of PAH by Therapies in USD Million (2016-2027)
Table 42 Italy Market size of PAH in USD Million (2016-2027)
Table 43 Italy Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Table 44 Italy market size of PAH by Therapies in USD Million (2016-2027)
Table 45 Spain Market size of PAH in USD Million (2016-2027)
Table 46 Spain Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Table 47 Spain market size of PAH by Therapies in USD Million (2016-2027)
Table 48 The UK Market size of PAH in USD Million (2016-2027)
Table 49 The UK Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Table 50 The UK market size of PAH by Therapies in USD Million (2016-2027)
Table 51 Japan Market size of PAH in USD Million (2016-2027)
Table 52 Japan Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Table 53 Japan market size of PAH by Therapies in USD Million (2016-2027)
Table 54 Rest of the World (RoW) Market size of PAH in USD Million (2016-2027)
Table 55 Rest of Europe (RoE), Market size of PAH in USD Million (2016-2027)
List of Figures:
Figure 1: Classification of Pulmonary Arterial Hypertension (PAH)
Figure 2: Functional Classification of PAH
Figure 3: Risk Factors of Pulmonary Arterial Hypertension
Figure 4: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
Figure 5: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 6: Total Prevalent Patient Population of PAH in 7MM (2016-2027)
Figure 7: Prevalence of PAH in the United States (2016-2027)
Figure 8: Sub-type Specific Prevalence of PAH in the United States (2016-2027)
Figure 9: Gender specific Prevalence of PAH in the United States (2016-2027)
Figure 10: Total Prevalent Population of PAH in Germany (2016-2027)
Figure 11: Sub-type Specific Prevalence of PAH in Germany (2016-2027)
Figure 12: Gender specific Prevalence of PAH in Germany (2016-2027)
Figure 13: Total Prevalent Population of PAH in France (2016-2027)
Figure 14: Sub-type Specific Prevalence of PAH in France (2016-2027)
Figure 15: Gender specific Prevalence of PAH in France (2016-2027)
Figure 16: Total Prevalent Population of PAH in Italy (2016-2027)
Figure 17: Sub-type Specific Prevalence of PAH in Italy (2016-2027)
Figure 18: Gender specific Prevalence of PAH in Italy (2016-2027)
Figure 19: Total Prevalent Population of PAH in Spain (2016-2027)
Figure 20: Sub-type Specific Prevalence of PAH in Spain (2016-2027)
Figure 21: Gender specific Prevalence of PAH in Spain (2016-2027)
Figure 22: Total Prevalent Population of PAH in the UK (2016-2027)
Figure 23: Sub-type Specific Prevalence of PAH in the UK (2016-2027)
Figure 24: Gender specific Prevalence of PAH in the United Kingdom (2016-2027)
Figure 25: Total Prevalent Population of PAH in Japan (2016-2027)
Figure 26: Sub-type Specific Prevalence of PAH in Japan (2016-2027)
Figure 27: Gender specific Prevalence of PAH in Japan (2016-2027)
Figure 28: Treatment Options for Pulmonary Arterial Hypertension (PAH)
Figure 29: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 30: Global Market Size of PAH USD Million (2016-2027)
Figure 31: Global Market Size of Pulmonary Arterial Hypertension (PAH) in USD Million (2015-2025)
Figure 32: 7 Major Market Size of PAH in USD Million (2016-2027)
Figure 33: Market Size of PAH in the United States, USD Millions (2016-2027)
Figure 34: The U.S. Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Figure 35: The U.S. market size of PAH by therapies in USD Million (2016-2027)
Figure 36: Market Size of PAH in Germany, USD Millions (2016-2027)
Figure 37: Germany Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Figure 38: Germany market size of PAH by therapies in USD Million (2016-2027)
Figure 39: Market Size of PAH in France, USD Millions (2016-2027)
Figure 40: France Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Figure 41: France market size of PAH by therapies in USD Million (2016-2027)
Figure 42: Market Size of PAH in Italy, USD Millions (2016-2027)
Figure 43: Italy Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Figure 44: Italy market size of PAH by therapies in USD Million (2016-2027)
Figure 45: Market Size of PAH in Spain, USD Millions (2016-2027)
Figure 46: Spain Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Figure 47: Spain market size of PAH by therapies in USD Million (2016-2027)
Figure 48: Market Size of PAH in the UK, USD Millions (2016-2027)
Figure 49: The UK Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Figure 50: The UK market size of PAH by therapies in USD Million (2016-2027)
Figure 51: Market Size of PAH in Japan, USD Millions (2016-2027)
Figure 52: Japan Market size of PAH by Therapeutic Class in USD Million (2016-2027)
Figure 53: Japan market size of PAH by therapies in USD Million (2016-2027)
Figure 54: Market Size of PAH in Rest of the World (RoW), USD Millions (2016-2027)
Figure 55: Market Size of PAH in Rest of Europe (RoE), USD Millions (2016-2027)
